Total Payments
$106,627
2024 Payments
$462.73
Companies
33
Transactions
624
Medicare Patients
3,390
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$83,875 (78.7%)
Food & Beverage$11,697 (11.0%)
Travel$7,861 (7.4%)
Research$3,173 (3.0%)
Education$21.21 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,875 | 48 | 78.7% |
| Food and Beverage | $11,697 | 524 | 11.0% |
| Travel and Lodging | $7,861 | 34 | 7.4% |
| Unspecified | $3,173 | 15 | 3.0% |
| Education | $21.21 | 3 | 0.0% |
Payments by Type
General
$103,454
609 transactions
Research
$3,173
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $83,800 | 131 | $0 (2024) |
| Genentech USA, Inc. | $12,175 | 78 | $0 (2024) |
| Eli Lilly and Company | $1,838 | 6 | $0 (2024) |
| ABBVIE INC. | $1,722 | 86 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,684 | 56 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,276 | 9 | $0 (2018) |
| PFIZER INC. | $1,138 | 100 | $0 (2023) |
| Janssen Biotech, Inc. | $712.28 | 15 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $709.79 | 50 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $240.09 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $462.73 | 17 | Eli Lilly and Company ($114.46) |
| 2023 | $1,148 | 45 | Janssen Biotech, Inc. ($296.76) |
| 2022 | $1,573 | 83 | ABBVIE INC. ($684.76) |
| 2021 | $1,120 | 63 | AbbVie Inc. ($238.42) |
| 2020 | $428.96 | 23 | AbbVie Inc. ($202.21) |
| 2019 | $29,836 | 111 | Amgen Inc. ($27,960) |
| 2018 | $20,904 | 131 | Amgen Inc. ($10,245) |
| 2017 | $51,154 | 151 | Amgen Inc. ($45,206) |
All Payment Transactions
624 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Dermatology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 08/27/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: IMMUNOLOGY | ||||||
| 08/16/2024 | Eli Lilly and Company | — | — | In-kind items and services | $114.46 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | ||||||
| 07/30/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: Inflammation | ||||||
| 07/08/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Endocrinology | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.06 | General |
| 05/30/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: IMMUNOLOGY | ||||||
| 05/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.64 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Not Applicable | ||||||
| 03/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: IMMUNOLOGY | ||||||
| 02/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.45 | General |
| 01/28/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Immunology | ||||||
| 01/19/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: IMMUNOLOGY | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Dermatology | ||||||
| 12/21/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $34.78 | General |
| Category: IMMUNOLOGY | ||||||
| 12/07/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Inflammation | ||||||
| 11/30/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Immunology | ||||||
| 11/30/2023 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Endocrinology | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $5.52 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis | SANOFI US SERVICES INC. | $1,276 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $896.35 | 1 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, | GlaxoSmithKline, LLC. | $885.37 | 4 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | Eli Lilly and Company | $114.46 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 807 | 24,225 | $1.5M | $600,539 |
| 2022 | 25 | 919 | 23,537 | $1.9M | $848,203 |
| 2021 | 19 | 782 | 19,592 | $1.8M | $712,508 |
| 2020 | 24 | 882 | 22,101 | $2.4M | $927,645 |
Total Patients
3,390
Total Services
89,455
Medicare Billing
$3.1M
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 20 | 7,525 | $523,740 | $248,412 | 47.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 15 | 3,830 | $243,205 | $100,458 | 41.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 62 | 5,400 | $198,558 | $95,194 | 47.9% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 5,750 | $130,700 | $60,304 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 193 | 381 | $103,453 | $36,481 | 35.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 70 | 286 | $165,880 | $31,204 | 18.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 80 | 176 | $25,520 | $10,345 | 40.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $15,050 | $4,784 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 50 | $9,204 | $3,269 | 35.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 26 | 121 | $24,200 | $2,830 | 11.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 23 | 35 | $7,263 | $2,165 | 29.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 59 | 139 | $1,390 | $1,168 | 84.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 23 | 23 | $4,701 | $916.32 | 19.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 12 | 12 | $960.00 | $863.16 | 89.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 17 | 57 | $3,248 | $730.75 | 22.5% |
| 73120 | X-ray of hand, 2 views | Office | 2023 | 12 | 24 | $1,585 | $597.72 | 37.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 16 | 16 | $1,025 | $496.64 | 48.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 18 | 150 | $1,500 | $126.84 | 8.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 53 | 193 | $3,088 | $97.33 | 3.2% |
| J1020 | Injection, methylprednisolone acetate, 20 mg | Office | 2023 | 13 | 21 | $185.43 | $96.04 | 51.8% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 24 | 10,325 | $718,620 | $354,997 | 49.4% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 13 | 3,280 | $410,000 | $218,433 | 53.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 17 | 3,110 | $197,485 | $88,993 | 45.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 60 | 5,100 | $187,527 | $83,558 | 44.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 203 | 387 | $105,082 | $37,379 | 35.6% |
About Dr. Christopher Antolini, MD
Dr. Christopher Antolini, MD is a Rheumatology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750302592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Antolini, MD has received a total of $106,627 in payments from pharmaceutical and medical device companies, with $462.73 received in 2024. These payments were reported across 624 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($83,875).
As a Medicare-enrolled provider, Antolini has provided services to 3,390 Medicare beneficiaries, totaling 89,455 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Denver, CO
- Active Since 07/21/2006
- Last Updated 09/06/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1750302592
Products in Payments
- Prolia (Biological) $53,245
- Enbrel (Biological) $17,083
- Actemra (Biological) $11,374
- BENLYSTA (Biological) $1,684
- EVENITY (Biological) $1,288
- KEVZARA (Drug) $1,276
- XELJANZ (Drug) $976.08
- TALTZ (Drug) $950.01
- RINVOQ (Biological) $797.02
- Rituxan (Biological) $777.76
- COSENTYX (Biological) $600.32
- TREMFYA (Drug) $346.11
- Humira (Biological) $314.50
- SKYRIZI (Biological) $271.39
- ORENCIA (Biological) $240.09
- SIMPONI ARIA (Biological) $213.06
- HUMIRA (Biological) $211.31
- Cimzia (Drug) $162.78
- REMICADE (Biological) $125.00
- COSENTYX (Drug) $109.47
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Denver
Dr. Aryeh Fischer, M.d, M.D
Rheumatology — Payments: $218,383
Rheumatology $218,383
Rennie Mccabe, Md, MD
Rheumatology — Payments: $76,484
Rheumatology $76,484
Barbara Goldstein, Md, MD
Rheumatology — Payments: $61,861
Rheumatology $61,861
Adam Berlinberg, Md, MD
Rheumatology — Payments: $41,589
Rheumatology $41,589
Vance Bray, Md, MD
Rheumatology — Payments: $35,851
Rheumatology $35,851
Dr. Mehrnaz Maleki Fischbach, Md, MD
Rheumatology — Payments: $25,005
Rheumatology $25,005